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Recent data suggest that patients suffering from Crohn’s disease (CD) may be at higher risk of developing
extra-intestinal malignancies. This is attributed to inﬂammation and immunodepression due to medi-
cations. However, a genetic predisposition cannot ruled out. In the present study we investigated the
prevalence of breast cancer in ﬁrst-degree female relatives of CD patients compared with relatives of
patients without evidence of gastrointestinal diseases. A total of 1302 female ﬁrst-degree relatives of CD
patients and 1294 relatives of controls were included. We found that CD was an independent risk factor
for breast cancer development (OR ¼ 2.76, 95% CI ¼ 1.2e6.2; p ¼ 0.017), and this is particularly evident in
mothers (3.6% vs 1%, p ¼ 0.009  OR ¼ 3.7, 95% CI 1.4e10). Among CD group, smoking habit of CD
patients was associated with increased risk of cancer compared with relatives of non-smokers (7.7% vs
2.9%, p ¼ 0.01 e OR ¼ 2.8 95% CI 1.2e6.6). Intriguingly, stage at diagnosis was signiﬁcantly higher in CD
relatives (p ¼ 0.04). Our ﬁndings suggest that ﬁrst-degree female relatives of CD patients are at higher
risk of developing breast cancer but receive diagnosis at more advanced stages, therefore advocating the
need of more active screening protocol in this population.
© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Crohn’s disease (CD) is an inﬂammatory bowel disease charac-
terized by chronic and relapsing inﬂammation. Recent studies
suggested that the risk of colorectal cancer in CD patients is lower
than previously thought, but these patients may have an excess risk
of extra-intestinal malignancies [1]. Cancer development in in-
ﬂammatory bowel diseases is different from sporadic cancer and is
strictly related with inﬂammation and disease duration [1]. The
increase in survival justiﬁes the higher rates of patients which are
being diagnosed in the elderly [2,3], who presumably have long-
standing, overlooked disease. Inﬂammatory bowel diseases are
also common in the childhood [4], and these patients are fated to
have long-lasting diseases. These observations suggest the impor-
tance of early diagnosis and screening; however, less attention is
paid to relatives of patients diagnosed with CD. It has beeni).
by Elsevier Ltd. All rights reservedsuggested that ﬁrst-degree relatives of CD patientsmay be at higher
risk of breast cancer [5].
Assuming that CD is an immune disease, and that immunolog-
ical disorders may be inherited and shared with other diseases, in
the present study we aimed to investigate the prevalence of breast
cancer in relatives of our CD patients compared with controls,
seeking for potential inﬂuence of CD.2. Material and methods
In this caseecontrol study, we prospectively collected clinical
data on consecutive CD patients admitted at our IBD referral Centre.
The prevalence of breast cancer in ﬁrst-degree female relatives was
investigated. A control group of parents of age-adjusted patients
with no evidence of gastro-intestinal diseases living in the same
geographic area was established.
Results were stratiﬁed according to age at diagnosis and disease
behaviour.
Five hundred and three outpatients (55% males, median age
36.2, range 3e87 years) with established diagnosis of CD referred at.
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were prospectively enrolled. Patients were not enrolled if theywere
diagnosed with cancer. Five hundred control patients (52% males,
median age 37.3, range 3e91 years) served as controls.
First-degree female relatives of included subjects were investi-
gated for breast malignancies, by means of a questionnaire sub-
mitted to patients. When needed, the general practitioners of the
relatives were contacted for additional information. A total of 1302
female ﬁrst-degree relatives of CD patients and 1294 relatives of
controls were included in ﬁnal analysis.
Clinical data of CD patients were collected and used for com-
parisons. Clinical and imaging data were matched with surgical
details, in order to compare the deﬁnitive stage of breast cancer
between groups.
2.1. Statistical analysis
Statistical analyses were performed by means of SPSS statistical
package (17 e SPSS Inc., Chicago, IL, USA). Continuous data are re-
ported asmedianwith range ormean ± SD. Univariate comparisons
between were performed with c2 test. The relative risk was
calculated and reported as Odds ratio (OR) with 95% conﬁdence
interval (95% CI). Continuous variables were compared by means of
Student’s t test. A value of p < 0.05 was considered as statistically
signiﬁcant. The impact of potential confounding known risk factors
for breast cancer was assessed by a logistic regression including CD.
3. Results
CD relatives group included 501 mothers, 541 sisters, and 260
daughters; 500 mothers, 539 sisters, and 255 daughters were
enrolled in control group.
We found 22 breast cancers (1.72%) in relatives of CD patients
and 8 (0.61%) in those of controls (OR ¼ 2.76, 95% CI ¼ 1.2e6.2;
p ¼ 0.017). Median ages at diagnosis of cancer did not differ be-
tween groups (53 vs 50, p > 0.99).
Cancer occurred in 18mothers (81.8%) and 4 sisters (18.2%) of CD
relatives, compared with 5 mothers (62.5%) and 3 sisters (37.5%) of
controls (p ¼ 0.34). Mothers of CD patients were at higher risk of
developing breast cancer than those of controls (3.6% vs 1%,
p ¼ 0.009  OR ¼ 3.7, 95% CI 1.4e10).
No differences were observed according to CD pattern and
localization, while CD diagnosis before 40 years of age exerted a
protective effect over breast cancer development (p¼ 0.03). Among
CD group, smoking habit of CD patients was associated with
increased risk of cancer compared with relatives of non-smokers
(7.7% vs 2.9%, p ¼ 0.01  OR ¼ 2.8 95% CI 1.2e6.6).
Stage at diagnosis was signiﬁcantly higher in CD relatives when
compared with controls (Stage I or cancer in situ: 4.5% vs 37.5%,
p ¼ 0.04).
All cases of breast cancer were included in a multivariate
regression analysis, which showed that a ﬁrst-degree relative with
CD was the only independent risk factor for breast cancer in this
population.
4. Discussion
With this caseecontrol study we were able to demonstrate an
increased risk of breast cancer in ﬁrst-degree relatives of patients
suffering from CD, irrespective of disease localization and behav-
iour, compared with controls. The former were more often diag-
nosed with advanced cancer stage.
Previous studies suggested an association between CD and
extra-intestinal malignancies (1). Riegler et al. (5) found that CD
relatives showa trend toward increased prevalence of cancers, evenif the observation did not reach statistical signiﬁcance. It was also
found that advanced age at diagnosis may be associated with
higher risk for cancer in ﬁrst-degree relatives [5]. The effect was
attributed by the older age of the subject as well as of the relatives.
This observation was conﬁrmed in the present series investigating
breast cancer. This ﬁnding should not be underestimated, given the
higher number of patients who are diagnosed with inﬂammatory
bowel diseases in the elderly [2,3] due to the improved disease
knowledge and to longer life expectancy. Moreover, optimal care is
pivotal also in this population, as age does not represent a limita-
tion for advanced procedure and treatment with curative intent
[2,3,6,7].
When considering colorectal cancer, the pathway leading to
cancer are different between CD and sporadic carcinoma [1]. CD
patients often receives many drugs for prolonged time during their
lives, which are active on the immune system [8,9], and these have
also been suggested by some authors to predispose to cancer, but
data are conﬂicting in the literature [1]. CD itself may play a role in
developing extra-intestinal malignancies, but the high rates of such
cancers in ﬁrst-degree relatives may suggest that CD could share
some genetic alterations with those underlying malignancies.
Breast cancer in these population was alarmingly high when
compared with controls. Mothers of CD patients had almost four
time the risk of developing breast cancer than controls. By
including all patients in a multivariate analysis, we were able to
exclude confounding factors, conﬁrming that only CD affecting a
relative was the independent risk factor for breast cancer. This
ﬁnding has an obvious practical implication, which is further
highlighted by considering that relatives of CD patients diagnosed
with breast cancer were eight times more likely receiving diagnosis
at more advanced stages (p ¼ 0.04). This impairs prognosis but also
reduces the possibility of a conservative surgical approach, and
advocates the need of diagnosing earlier breast cancer in these
subjects.
A common genetic susceptibility to inﬂammatory bowel dis-
eases and breast cancer has been hypothesized by some Japanese
authors, and related to interleukin-1 (IL-1) polymorphism [10]. ILs
play a central role in inﬂammatory bowel diseases as well as in-
ﬂammatory cytokines and mediators, although the clinical picture
may be silent [11]. Recent molecular evidences showed that these
factors are also involved in breast malignancies, and a shift of the
treatment toward a more tailored, immune-pathological approach
is being observed in the recent years [12]. This is not surprising, as
modiﬁcation in the same gene (MLH1) has been associated with
susceptibility to inﬂammatory bowel diseases and HNPCC, a syn-
drome predisposing to extra-intestinal malignancies [13,14]. These
data make the fascinating hypothesis of a common genetic aeti-
ology between CD and breast cancer more consistent.
Cigarette smoking is a known risk factor for developing CD and
is associated with higher rates of relapse after treatment. Active
smoking is a risk factor for many malignancies. Aiming to identify
familial factors whichmay play a role in breast cancer development
of CD relatives, we only took into account smoking habit of CD
patients, and found that passive smoking was associated with
almost three fold higher risk of developing breast cancer in this
subgroup compared with non-smoker counterparts. This is
consistent with recent evidences in Chinese women [15], and adds
another reason for encouraging smoking discontinuation in CD
patients.
Relatives of patients suffering from inﬂammatory bowel dis-
eases are often neglected. However, these should be considered
diseases involving the entire family group, and it has been recently
reported that disease activity and patients quality of life is reﬂected
by that of their ﬁrst-degree relatives, such as parents [4]. This
suggest the importance of actively involving relatives in the
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developing malignancies presumably due to a genetic predisposi-
tion, relatives should also receive an active screening protocol.
Our ﬁndings highlight the higher risk of developing breast
cancer in ﬁrst-degree female relatives of CD patients. When
compared with controls, these tended to have more advanced
disease at diagnosis. This may impair radicality of treatment, and
advocates the need for obtaining earlier the diagnosis in these
patients. It seems prudent to recommend close and active
screening for breast cancer in relatives of CD patients.
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